#begin document (wsj_1934.en); part 000
wsj_1934.en	0	0	A	DT	*	_	_	3	_	(3
wsj_1934.en	0	1	new	JJ	*	_	_	3	_	-
wsj_1934.en	0	2	drug	NN	*	_	_	14	_	3)
wsj_1934.en	0	3	to	TO	*	_	_	3	_	-
wsj_1934.en	0	4	prevent	VB	*	_	_	4	_	-
wsj_1934.en	0	5	the	DT	*	_	_	7	_	-
wsj_1934.en	0	6	rejection	NN	*	_	_	5	_	-
wsj_1934.en	0	7	of	IN	*	_	_	7	_	-
wsj_1934.en	0	8	transplanted	JJ	*	_	_	10	_	-
wsj_1934.en	0	9	organs	NNS	*	_	_	8	_	-
wsj_1934.en	0	10	has	VBZ	*	_	_	14	_	-
wsj_1934.en	0	11	been	VBN	*	_	_	14	_	-
wsj_1934.en	0	12	successfully	RB	*	_	_	14	_	-
wsj_1934.en	0	13	used	VBN	*	_	_	0	_	-
wsj_1934.en	0	14	on	IN	*	_	_	14	_	-
wsj_1934.en	0	15	more	JJR	*	_	_	17	_	(1
wsj_1934.en	0	16	than	IN	*	_	_	19	_	-
wsj_1934.en	0	17	100	CD	*	_	_	17	_	-
wsj_1934.en	0	18	patients	NNS	*	_	_	15	_	1)
wsj_1934.en	0	19	at	IN	*	_	_	14	_	-
wsj_1934.en	0	20	the	DT	*	_	_	22	_	(2
wsj_1934.en	0	21	University	NNP	*	_	_	20	_	-
wsj_1934.en	0	22	of	IN	*	_	_	22	_	-
wsj_1934.en	0	23	Pittsburgh	NNP	*	_	_	23	_	2)
wsj_1934.en	0	24	,	,	*	_	_	14	_	-
wsj_1934.en	0	25	according	VBG	*	_	_	14	_	-
wsj_1934.en	0	26	to	TO	*	_	_	26	_	-
wsj_1934.en	0	27	researchers	NNS	*	_	_	27	_	-
wsj_1934.en	0	28	.	.	*	_	_	14	_	-

wsj_1934.en	0	0	The	DT	*	_	_	31	_	(3
wsj_1934.en	0	1	drug	NN	*	_	_	44	_	-
wsj_1934.en	0	2	,	,	*	_	_	31	_	3)
wsj_1934.en	0	3	which	WDT	*	_	_	34	_	(3)
wsj_1934.en	0	4	is	VBZ	*	_	_	31	_	-
wsj_1934.en	0	5	still	RB	*	_	_	34	_	-
wsj_1934.en	0	6	in	IN	*	_	_	34	_	-
wsj_1934.en	0	7	the	DT	*	_	_	39	_	-
wsj_1934.en	0	8	experimental	JJ	*	_	_	39	_	-
wsj_1934.en	0	9	phase	NN	*	_	_	36	_	-
wsj_1934.en	0	10	,	,	*	_	_	31	_	-
wsj_1934.en	0	11	has	VBZ	*	_	_	44	_	-
wsj_1934.en	0	12	n't	RB	*	_	_	44	_	-
wsj_1934.en	0	13	been	VBN	*	_	_	44	_	-
wsj_1934.en	0	14	approved	VBN	*	_	_	53	_	-
wsj_1934.en	0	15	yet	RB	*	_	_	44	_	-
wsj_1934.en	0	16	by	IN	*	_	_	44	_	-
wsj_1934.en	0	17	the	DT	*	_	_	51	_	(9
wsj_1934.en	0	18	Food	NNP	*	_	_	49	_	-
wsj_1934.en	0	19	and	CC	*	_	_	51	_	-
wsj_1934.en	0	20	Drug	NNP	*	_	_	49	_	-
wsj_1934.en	0	21	Admistration	NNP	*	_	_	46	_	9)
wsj_1934.en	0	22	,	,	*	_	_	53	_	-
wsj_1934.en	0	23	and	CC	*	_	_	0	_	-
wsj_1934.en	0	24	its	PRP$	*	_	_	56	_	(3)
wsj_1934.en	0	25	long-term	JJ	*	_	_	56	_	-
wsj_1934.en	0	26	effects	NNS	*	_	_	57	_	-
wsj_1934.en	0	27	are	VBP	*	_	_	53	_	-
wsj_1934.en	0	28	unknown	JJ	*	_	_	57	_	-
wsj_1934.en	0	29	.	.	*	_	_	53	_	-

wsj_1934.en	0	0	But	CC	*	_	_	62	_	-
wsj_1934.en	0	1	researchers	NNS	*	_	_	62	_	-
wsj_1934.en	0	2	say	VBP	*	_	_	69	_	-
wsj_1934.en	0	3	the	DT	*	_	_	64	_	(3
wsj_1934.en	0	4	drug	NN	*	_	_	69	_	3)
wsj_1934.en	0	5	,	,	*	_	_	64	_	-
wsj_1934.en	0	6	called	VBN	*	_	_	64	_	-
wsj_1934.en	0	7	FK-506	NNP	*	_	_	66	_	-
wsj_1934.en	0	8	,	,	*	_	_	64	_	-
wsj_1934.en	0	9	could	MD	*	_	_	0	_	-
wsj_1934.en	0	10	revolutionize	VB	*	_	_	69	_	-
wsj_1934.en	0	11	the	DT	*	_	_	73	_	-
wsj_1934.en	0	12	transplantation	NN	*	_	_	73	_	-
wsj_1934.en	0	13	field	NN	*	_	_	70	_	-
wsj_1934.en	0	14	by	IN	*	_	_	79	_	-
wsj_1934.en	0	15	reducing	VBG	*	_	_	74	_	-
wsj_1934.en	0	16	harmful	JJ	*	_	_	78	_	-
wsj_1934.en	0	17	side	JJ	*	_	_	78	_	-
wsj_1934.en	0	18	effects	NNS	*	_	_	75	_	-
wsj_1934.en	0	19	and	CC	*	_	_	70	_	-
wsj_1934.en	0	20	by	IN	*	_	_	79	_	-
wsj_1934.en	0	21	lowering	VBG	*	_	_	80	_	-
wsj_1934.en	0	22	rejection	NN	*	_	_	83	_	-
wsj_1934.en	0	23	rates	NNS	*	_	_	81	_	-
wsj_1934.en	0	24	.	.	*	_	_	69	_	-

wsj_1934.en	0	0	Rejection	NN	*	_	_	87	_	-
wsj_1934.en	0	1	has	VBZ	*	_	_	87	_	-
wsj_1934.en	0	2	been	VBN	*	_	_	0	_	-
wsj_1934.en	0	3	the	DT	*	_	_	90	_	-
wsj_1934.en	0	4	major	JJ	*	_	_	90	_	-
wsj_1934.en	0	5	obstacle	NN	*	_	_	87	_	-
wsj_1934.en	0	6	in	IN	*	_	_	87	_	-
wsj_1934.en	0	7	the	DT	*	_	_	96	_	(19
wsj_1934.en	0	8	approximately	RB	*	_	_	94	_	-
wsj_1934.en	0	9	30,000	CD	*	_	_	96	_	-
wsj_1934.en	0	10	organ	NN	*	_	_	96	_	-
wsj_1934.en	0	11	transplants	NNS	*	_	_	91	_	19)
wsj_1934.en	0	12	performed	VBN	*	_	_	96	_	-
wsj_1934.en	0	13	world-wide	RB	*	_	_	97	_	-
wsj_1934.en	0	14	each	DT	*	_	_	100	_	-
wsj_1934.en	0	15	year	NN	*	_	_	97	_	-
wsj_1934.en	0	16	.	.	*	_	_	87	_	-

wsj_1934.en	0	0	Researchers	NNS	*	_	_	103	_	(20)
wsj_1934.en	0	1	began	VBD	*	_	_	0	_	-
wsj_1934.en	0	2	using	VBG	*	_	_	103	_	-
wsj_1934.en	0	3	the	DT	*	_	_	106	_	(3
wsj_1934.en	0	4	drug	NN	*	_	_	104	_	3)
wsj_1934.en	0	5	in	IN	*	_	_	103	_	-
wsj_1934.en	0	6	February	NNP	*	_	_	107	_	-
wsj_1934.en	0	7	on	IN	*	_	_	103	_	-
wsj_1934.en	0	8	patients	NNS	*	_	_	109	_	(21)
wsj_1934.en	0	9	who	WP	*	_	_	113	_	(21)
wsj_1934.en	0	10	had	VBD	*	_	_	113	_	-
wsj_1934.en	0	11	received	VBN	*	_	_	110	_	-
wsj_1934.en	0	12	kidney	NN	*	_	_	119	_	-
wsj_1934.en	0	13	,	,	*	_	_	119	_	-
wsj_1934.en	0	14	liver	NN	*	_	_	119	_	-
wsj_1934.en	0	15	,	,	*	_	_	119	_	-
wsj_1934.en	0	16	heart	NN	*	_	_	119	_	-
wsj_1934.en	0	17	and	CC	*	_	_	121	_	-
wsj_1934.en	0	18	pancreas	NN	*	_	_	119	_	-
wsj_1934.en	0	19	transplants	NNS	*	_	_	113	_	-
wsj_1934.en	0	20	.	.	*	_	_	103	_	-

wsj_1934.en	0	0	Only	RB	*	_	_	125	_	-
wsj_1934.en	0	1	two	CD	*	_	_	125	_	-
wsj_1934.en	0	2	of	IN	*	_	_	127	_	-
wsj_1934.en	0	3	111	CD	*	_	_	125	_	-
wsj_1934.en	0	4	transplants	NNS	*	_	_	130	_	-
wsj_1934.en	0	5	have	VBP	*	_	_	130	_	-
wsj_1934.en	0	6	been	VBN	*	_	_	130	_	-
wsj_1934.en	0	7	rejected	VBN	*	_	_	0	_	-
wsj_1934.en	0	8	.	.	*	_	_	130	_	-

wsj_1934.en	0	0	The	DT	*	_	_	133	_	(3
wsj_1934.en	0	1	drug	NN	*	_	_	140	_	3)
wsj_1934.en	0	2	,	,	*	_	_	133	_	-
wsj_1934.en	0	3	discovered	VBN	*	_	_	133	_	-
wsj_1934.en	0	4	in	IN	*	_	_	135	_	-
wsj_1934.en	0	5	1984	CD	*	_	_	136	_	-
wsj_1934.en	0	6	,	,	*	_	_	133	_	-
wsj_1934.en	0	7	is	VBZ	*	_	_	140	_	-
wsj_1934.en	0	8	metabolized	VBN	*	_	_	0	_	-
wsj_1934.en	0	9	from	IN	*	_	_	140	_	-
wsj_1934.en	0	10	soil	NN	*	_	_	143	_	(22
wsj_1934.en	0	11	fungus	NN	*	_	_	141	_	22)
wsj_1934.en	0	12	found	VBN	*	_	_	143	_	-
wsj_1934.en	0	13	in	IN	*	_	_	144	_	-
wsj_1934.en	0	14	Japan	NNP	*	_	_	145	_	-
wsj_1934.en	0	15	.	.	*	_	_	140	_	-

wsj_1934.en	0	0	The	DT	*	_	_	150	_	(1
wsj_1934.en	0	1	Pittsburgh	NNP	*	_	_	150	_	(2)
wsj_1934.en	0	2	patients	NNS	*	_	_	151	_	1)
wsj_1934.en	0	3	are	VBP	*	_	_	0	_	-
wsj_1934.en	0	4	the	DT	*	_	_	154	_	(23
wsj_1934.en	0	5	first	JJ	*	_	_	154	_	-
wsj_1934.en	0	6	humans	NNS	*	_	_	151	_	23)
wsj_1934.en	0	7	to	TO	*	_	_	154	_	-
wsj_1934.en	0	8	be	VB	*	_	_	157	_	-
wsj_1934.en	0	9	given	VBN	*	_	_	155	_	-
wsj_1934.en	0	10	the	DT	*	_	_	159	_	(3
wsj_1934.en	0	11	drug	NN	*	_	_	157	_	3)
wsj_1934.en	0	12	,	,	*	_	_	159	_	-
wsj_1934.en	0	13	which	WDT	*	_	_	163	_	(3)
wsj_1934.en	0	14	is	VBZ	*	_	_	163	_	-
wsj_1934.en	0	15	made	VBN	*	_	_	159	_	-
wsj_1934.en	0	16	by	IN	*	_	_	163	_	-
wsj_1934.en	0	17	Fujisawa	NNP	*	_	_	166	_	(16
wsj_1934.en	0	18	Pharmaceutical	NNP	*	_	_	167	_	-
wsj_1934.en	0	19	Co	NNP	*	_	_	164	_	16)
wsj_1934.en	0	20	.	.	*	_	_	151	_	-

wsj_1934.en	0	0	``	``	*	_	_	184	_	-
wsj_1934.en	0	1	We	PRP	*	_	_	172	_	(5)
wsj_1934.en	0	2	're	VBP	*	_	_	172	_	-
wsj_1934.en	0	3	shocked	JJ	*	_	_	184	_	-
wsj_1934.en	0	4	by	IN	*	_	_	172	_	-
wsj_1934.en	0	5	it	PRP	*	_	_	173	_	(3)
wsj_1934.en	0	6	,	,	*	_	_	172	_	-
wsj_1934.en	0	7	because	IN	*	_	_	172	_	-
wsj_1934.en	0	8	it	PRP	*	_	_	179	_	(3)
wsj_1934.en	0	9	's	VBZ	*	_	_	179	_	-
wsj_1934.en	0	10	worked	VBN	*	_	_	176	_	-
wsj_1934.en	0	11	so	RB	*	_	_	181	_	-
wsj_1934.en	0	12	fast	RB	*	_	_	179	_	-
wsj_1934.en	0	13	,	,	*	_	_	184	_	-
wsj_1934.en	0	14	''	''	*	_	_	184	_	-
wsj_1934.en	0	15	said	VBD	*	_	_	0	_	-
wsj_1934.en	0	16	Dr.	NNP	*	_	_	188	_	(8
wsj_1934.en	0	17	Thomas	NNP	*	_	_	188	_	-
wsj_1934.en	0	18	E.	NNP	*	_	_	188	_	-
wsj_1934.en	0	19	Starzl	NNP	*	_	_	189	_	8)
wsj_1934.en	0	20	,	,	*	_	_	184	_	-
wsj_1934.en	0	21	director	NN	*	_	_	189	_	(8
wsj_1934.en	0	22	of	IN	*	_	_	190	_	-
wsj_1934.en	0	23	the	DT	*	_	_	197	_	(10
wsj_1934.en	0	24	University	NNP	*	_	_	197	_	-
wsj_1934.en	0	25	of	IN	*	_	_	193	_	-
wsj_1934.en	0	26	Pittsburgh	NNP	*	_	_	194	_	-
wsj_1934.en	0	27	Transplantation	NNP	*	_	_	197	_	-
wsj_1934.en	0	28	Program	NNP	*	_	_	191	_	8)|10)
wsj_1934.en	0	29	,	,	*	_	_	190	_	-
wsj_1934.en	0	30	at	IN	*	_	_	184	_	-
wsj_1934.en	0	31	a	DT	*	_	_	202	_	-
wsj_1934.en	0	32	news	NN	*	_	_	202	_	-
wsj_1934.en	0	33	conference	NN	*	_	_	199	_	-
wsj_1934.en	0	34	here	RB	*	_	_	184	_	-
wsj_1934.en	0	35	yesterday	NN	*	_	_	184	_	-
wsj_1934.en	0	36	.	.	*	_	_	184	_	-

wsj_1934.en	0	0	``	``	*	_	_	220	_	-
wsj_1934.en	0	1	We	PRP	*	_	_	208	_	(5)
wsj_1934.en	0	2	consider	VBP	*	_	_	220	_	-
wsj_1934.en	0	3	it	PRP	*	_	_	208	_	(3)
wsj_1934.en	0	4	a	DT	*	_	_	212	_	-
wsj_1934.en	0	5	life-saving	JJ	*	_	_	212	_	-
wsj_1934.en	0	6	drug	NN	*	_	_	209	_	-
wsj_1934.en	0	7	,	,	*	_	_	212	_	-
wsj_1934.en	0	8	like	IN	*	_	_	212	_	-
wsj_1934.en	0	9	one	CD	*	_	_	214	_	-
wsj_1934.en	0	10	for	IN	*	_	_	215	_	-
wsj_1934.en	0	11	AIDS	NNP	*	_	_	216	_	-
wsj_1934.en	0	12	,	,	*	_	_	220	_	-
wsj_1934.en	0	13	''	''	*	_	_	220	_	-
wsj_1934.en	0	14	said	VBD	*	_	_	0	_	-
wsj_1934.en	0	15	Dr.	NNP	*	_	_	223	_	(4
wsj_1934.en	0	16	John	NNP	*	_	_	223	_	-
wsj_1934.en	0	17	Fung	NNP	*	_	_	224	_	4)
wsj_1934.en	0	18	,	,	*	_	_	220	_	-
wsj_1934.en	0	19	an	DT	*	_	_	226	_	(4
wsj_1934.en	0	20	immunologist	NN	*	_	_	224	_	-
wsj_1934.en	0	21	at	IN	*	_	_	226	_	-
wsj_1934.en	0	22	the	DT	*	_	_	229	_	(2
wsj_1934.en	0	23	University	NNP	*	_	_	227	_	-
wsj_1934.en	0	24	of	IN	*	_	_	229	_	-
wsj_1934.en	0	25	Pittsburgh	NNP	*	_	_	230	_	2)|4)
wsj_1934.en	0	26	.	.	*	_	_	220	_	-

wsj_1934.en	0	0	Researchers	NNS	*	_	_	234	_	(6)
wsj_1934.en	0	1	say	VBP	*	_	_	0	_	-
wsj_1934.en	0	2	they	PRP	*	_	_	236	_	(6)
wsj_1934.en	0	3	believe	VBP	*	_	_	234	_	-
wsj_1934.en	0	4	FK-506	NNP	*	_	_	238	_	(3)
wsj_1934.en	0	5	is	VBZ	*	_	_	236	_	-
wsj_1934.en	0	6	100	CD	*	_	_	242	_	-
wsj_1934.en	0	7	times	NNS	*	_	_	239	_	-
wsj_1934.en	0	8	more	RBR	*	_	_	242	_	-
wsj_1934.en	0	9	effective	JJ	*	_	_	238	_	-
wsj_1934.en	0	10	than	IN	*	_	_	242	_	-
wsj_1934.en	0	11	the	DT	*	_	_	247	_	(7|(7
wsj_1934.en	0	12	traditional	JJ	*	_	_	247	_	-
wsj_1934.en	0	13	anti-rejection	JJ	*	_	_	247	_	-
wsj_1934.en	0	14	drug	NN	*	_	_	249	_	7)
wsj_1934.en	0	15	,	,	*	_	_	249	_	-
wsj_1934.en	0	16	cyclosporine	NN	*	_	_	243	_	7)
wsj_1934.en	0	17	,	,	*	_	_	249	_	-
wsj_1934.en	0	18	made	VBN	*	_	_	249	_	-
wsj_1934.en	0	19	by	IN	*	_	_	251	_	-
wsj_1934.en	0	20	Swiss	JJ	*	_	_	255	_	-
wsj_1934.en	0	21	pharmaceutical	JJ	*	_	_	255	_	-
wsj_1934.en	0	22	giant	NN	*	_	_	257	_	-
wsj_1934.en	0	23	Sandoz	NNP	*	_	_	257	_	-
wsj_1934.en	0	24	Ltd	NNP	*	_	_	252	_	-
wsj_1934.en	0	25	.	.	*	_	_	234	_	-

wsj_1934.en	0	0	They	PRP	*	_	_	262	_	(6)
wsj_1934.en	0	1	are	VBP	*	_	_	262	_	-
wsj_1934.en	0	2	also	RB	*	_	_	262	_	-
wsj_1934.en	0	3	encouraged	VBN	*	_	_	0	_	-
wsj_1934.en	0	4	by	IN	*	_	_	262	_	-
wsj_1934.en	0	5	the	DT	*	_	_	268	_	-
wsj_1934.en	0	6	relatively	RB	*	_	_	266	_	-
wsj_1934.en	0	7	mild	JJ	*	_	_	268	_	-
wsj_1934.en	0	8	side	JJ	*	_	_	268	_	-
wsj_1934.en	0	9	effects	NNS	*	_	_	263	_	-
wsj_1934.en	0	10	of	IN	*	_	_	268	_	-
wsj_1934.en	0	11	FK-506	NNP	*	_	_	269	_	(3)
wsj_1934.en	0	12	,	,	*	_	_	268	_	-
wsj_1934.en	0	13	compared	VBN	*	_	_	268	_	(7
wsj_1934.en	0	14	with	IN	*	_	_	272	_	-
wsj_1934.en	0	15	cyclosporine	NN	*	_	_	273	_	7)
wsj_1934.en	0	16	,	,	*	_	_	274	_	-
wsj_1934.en	0	17	which	WDT	*	_	_	277	_	(7)
wsj_1934.en	0	18	can	MD	*	_	_	274	_	-
wsj_1934.en	0	19	cause	VB	*	_	_	277	_	-
wsj_1934.en	0	20	renal	JJ	*	_	_	280	_	-
wsj_1934.en	0	21	failure	NN	*	_	_	285	_	-
wsj_1934.en	0	22	,	,	*	_	_	285	_	-
wsj_1934.en	0	23	morbidity	NN	*	_	_	285	_	-
wsj_1934.en	0	24	,	,	*	_	_	285	_	-
wsj_1934.en	0	25	nausea	NN	*	_	_	285	_	-
wsj_1934.en	0	26	and	CC	*	_	_	278	_	-
wsj_1934.en	0	27	other	JJ	*	_	_	287	_	-
wsj_1934.en	0	28	problems	NNS	*	_	_	285	_	-
wsj_1934.en	0	29	.	.	*	_	_	262	_	-

wsj_1934.en	0	0	``	``	*	_	_	310	_	-
wsj_1934.en	0	1	The	DT	*	_	_	292	_	-
wsj_1934.en	0	2	side	JJ	*	_	_	292	_	-
wsj_1934.en	0	3	effects	NNS	*	_	_	298	_	-
wsj_1934.en	0	4	-LCB-	-LRB-	*	_	_	292	_	-
wsj_1934.en	0	5	of	IN	*	_	_	293	_	-
wsj_1934.en	0	6	cyclosporine	NN	*	_	_	294	_	(7)
wsj_1934.en	0	7	-RCB-	-RRB-	*	_	_	293	_	-
wsj_1934.en	0	8	have	VBP	*	_	_	298	_	-
wsj_1934.en	0	9	made	VBN	*	_	_	310	_	-
wsj_1934.en	0	10	the	DT	*	_	_	300	_	-
wsj_1934.en	0	11	penalty	NN	*	_	_	298	_	-
wsj_1934.en	0	12	for	IN	*	_	_	300	_	-
wsj_1934.en	0	13	its	PRP$	*	_	_	303	_	(7)
wsj_1934.en	0	14	success	NN	*	_	_	301	_	-
wsj_1934.en	0	15	rather	RB	*	_	_	305	_	-
wsj_1934.en	0	16	high	JJ	*	_	_	300	_	-
wsj_1934.en	0	17	,	,	*	_	_	310	_	-
wsj_1934.en	0	18	''	''	*	_	_	310	_	-
wsj_1934.en	0	19	Dr.	NNP	*	_	_	309	_	(8
wsj_1934.en	0	20	Starzl	NNP	*	_	_	310	_	8)
wsj_1934.en	0	21	said	VBD	*	_	_	0	_	-
wsj_1934.en	0	22	.	.	*	_	_	310	_	-

wsj_1934.en	0	0	Dr.	NNP	*	_	_	313	_	(4
wsj_1934.en	0	1	Fung	NNP	*	_	_	314	_	4)
wsj_1934.en	0	2	said	VBD	*	_	_	0	_	-
wsj_1934.en	0	3	that	IN	*	_	_	330	_	-
wsj_1934.en	0	4	FK-506	NNP	*	_	_	317	_	(3)
wsj_1934.en	0	5	would	MD	*	_	_	315	_	-
wsj_1934.en	0	6	not	RB	*	_	_	317	_	-
wsj_1934.en	0	7	be	VB	*	_	_	317	_	-
wsj_1934.en	0	8	available	JJ	*	_	_	319	_	-
wsj_1934.en	0	9	in	IN	*	_	_	319	_	-
wsj_1934.en	0	10	the	DT	*	_	_	323	_	-
wsj_1934.en	0	11	market	NN	*	_	_	321	_	-
wsj_1934.en	0	12	for	IN	*	_	_	319	_	-
wsj_1934.en	0	13	at	IN	*	_	_	328	_	-
wsj_1934.en	0	14	least	JJS	*	_	_	325	_	-
wsj_1934.en	0	15	a	DT	*	_	_	325	_	-
wsj_1934.en	0	16	year	NN	*	_	_	324	_	-
wsj_1934.en	0	17	,	,	*	_	_	330	_	-
wsj_1934.en	0	18	and	CC	*	_	_	314	_	-
wsj_1934.en	0	19	that	IN	*	_	_	330	_	-
wsj_1934.en	0	20	the	DT	*	_	_	335	_	-
wsj_1934.en	0	21	FDA	NNP	*	_	_	334	_	(9)
wsj_1934.en	0	22	approval	NN	*	_	_	335	_	-
wsj_1934.en	0	23	process	NN	*	_	_	337	_	-
wsj_1934.en	0	24	usually	RB	*	_	_	337	_	-
wsj_1934.en	0	25	takes	VBZ	*	_	_	331	_	-
wsj_1934.en	0	26	three	CD	*	_	_	339	_	-
wsj_1934.en	0	27	years	NNS	*	_	_	340	_	-
wsj_1934.en	0	28	to	TO	*	_	_	337	_	-
wsj_1934.en	0	29	five	CD	*	_	_	342	_	-
wsj_1934.en	0	30	years	NNS	*	_	_	340	_	-
wsj_1934.en	0	31	.	.	*	_	_	314	_	-

wsj_1934.en	0	0	There	EX	*	_	_	345	_	-
wsj_1934.en	0	1	are	VBP	*	_	_	0	_	-
wsj_1934.en	0	2	no	DT	*	_	_	348	_	-
wsj_1934.en	0	3	firm	JJ	*	_	_	348	_	-
wsj_1934.en	0	4	plans	NNS	*	_	_	345	_	-
wsj_1934.en	0	5	to	TO	*	_	_	348	_	-
wsj_1934.en	0	6	expand	VB	*	_	_	349	_	-
wsj_1934.en	0	7	the	DT	*	_	_	353	_	(10
wsj_1934.en	0	8	experimental	JJ	*	_	_	353	_	-
wsj_1934.en	0	9	program	NN	*	_	_	350	_	10)
wsj_1934.en	0	10	beyond	IN	*	_	_	350	_	-
wsj_1934.en	0	11	the	DT	*	_	_	356	_	(2
wsj_1934.en	0	12	University	NNP	*	_	_	354	_	-
wsj_1934.en	0	13	of	IN	*	_	_	356	_	-
wsj_1934.en	0	14	Pittsburgh	NNP	*	_	_	357	_	2)
wsj_1934.en	0	15	,	,	*	_	_	356	_	-
wsj_1934.en	0	16	whose	WP$	*	_	_	362	_	(2)|(11
wsj_1934.en	0	17	hospital	NN	*	_	_	360	_	11)
wsj_1934.en	0	18	performs	VBZ	*	_	_	356	_	-
wsj_1934.en	0	19	the	DT	*	_	_	365	_	-
wsj_1934.en	0	20	most	JJS	*	_	_	365	_	-
wsj_1934.en	0	21	transplants	NNS	*	_	_	362	_	-
wsj_1934.en	0	22	in	IN	*	_	_	365	_	-
wsj_1934.en	0	23	the	DT	*	_	_	368	_	-
wsj_1934.en	0	24	world	NN	*	_	_	366	_	-
wsj_1934.en	0	25	.	.	*	_	_	345	_	-

wsj_1934.en	0	0	Researchers	NNS	*	_	_	371	_	(13)
wsj_1934.en	0	1	could	MD	*	_	_	385	_	-
wsj_1934.en	0	2	n't	RB	*	_	_	371	_	-
wsj_1934.en	0	3	estimate	VB	*	_	_	371	_	-
wsj_1934.en	0	4	the	DT	*	_	_	375	_	-
wsj_1934.en	0	5	cost	NN	*	_	_	373	_	-
wsj_1934.en	0	6	of	IN	*	_	_	375	_	-
wsj_1934.en	0	7	the	DT	*	_	_	378	_	(3
wsj_1934.en	0	8	drug	NN	*	_	_	376	_	3)
wsj_1934.en	0	9	when	WRB	*	_	_	381	_	-
wsj_1934.en	0	10	it	PRP	*	_	_	381	_	(3)
wsj_1934.en	0	11	reaches	VBZ	*	_	_	375	_	-
wsj_1934.en	0	12	the	DT	*	_	_	383	_	-
wsj_1934.en	0	13	market	NN	*	_	_	381	_	-
wsj_1934.en	0	14	,	,	*	_	_	385	_	-
wsj_1934.en	0	15	but	CC	*	_	_	0	_	-
wsj_1934.en	0	16	they	PRP	*	_	_	387	_	(13)
wsj_1934.en	0	17	said	VBD	*	_	_	385	_	-
wsj_1934.en	0	18	FK-506	NNP	*	_	_	399	_	(3)
wsj_1934.en	0	19	will	MD	*	_	_	399	_	-
wsj_1934.en	0	20	enable	VB	*	_	_	399	_	-
wsj_1934.en	0	21	patients	NNS	*	_	_	392	_	(14)
wsj_1934.en	0	22	to	TO	*	_	_	390	_	-
wsj_1934.en	0	23	cut	VB	*	_	_	392	_	-
wsj_1934.en	0	24	hospital	NN	*	_	_	395	_	-
wsj_1934.en	0	25	stays	NNS	*	_	_	393	_	-
wsj_1934.en	0	26	by	IN	*	_	_	393	_	-
wsj_1934.en	0	27	50	CD	*	_	_	398	_	-
wsj_1934.en	0	28	%	NN	*	_	_	396	_	-
wsj_1934.en	0	29	and	CC	*	_	_	387	_	-
wsj_1934.en	0	30	reduce	VB	*	_	_	399	_	-
wsj_1934.en	0	31	the	DT	*	_	_	402	_	-
wsj_1934.en	0	32	number	NN	*	_	_	400	_	-
wsj_1934.en	0	33	of	IN	*	_	_	402	_	-
wsj_1934.en	0	34	blood	NN	*	_	_	405	_	(15
wsj_1934.en	0	35	tests	NNS	*	_	_	403	_	15)
wsj_1934.en	0	36	used	VBN	*	_	_	405	_	-
wsj_1934.en	0	37	to	TO	*	_	_	406	_	-
wsj_1934.en	0	38	monitor	VB	*	_	_	407	_	-
wsj_1934.en	0	39	the	DT	*	_	_	410	_	-
wsj_1934.en	0	40	dosage	NN	*	_	_	408	_	-
wsj_1934.en	0	41	of	IN	*	_	_	410	_	-
wsj_1934.en	0	42	cyclosporine	JJ	*	_	_	413	_	(7)
wsj_1934.en	0	43	and	CC	*	_	_	411	_	-
wsj_1934.en	0	44	other	JJ	*	_	_	415	_	(3
wsj_1934.en	0	45	drugs	NNS	*	_	_	413	_	3)
wsj_1934.en	0	46	among	IN	*	_	_	406	_	-
wsj_1934.en	0	47	transplant	NN	*	_	_	418	_	-
wsj_1934.en	0	48	recipients	NNS	*	_	_	416	_	-
wsj_1934.en	0	49	.	.	*	_	_	385	_	-

wsj_1934.en	0	0	Dr.	NNP	*	_	_	421	_	(8
wsj_1934.en	0	1	Starzl	NNP	*	_	_	422	_	8)
wsj_1934.en	0	2	said	VBD	*	_	_	0	_	-
wsj_1934.en	0	3	the	DT	*	_	_	424	_	(17
wsj_1934.en	0	4	research	NN	*	_	_	428	_	17)
wsj_1934.en	0	5	has	VBZ	*	_	_	428	_	-
wsj_1934.en	0	6	been	VBN	*	_	_	428	_	-
wsj_1934.en	0	7	largely	RB	*	_	_	428	_	-
wsj_1934.en	0	8	financed	VBN	*	_	_	440	_	-
wsj_1934.en	0	9	by	IN	*	_	_	435	_	-
wsj_1934.en	0	10	the	DT	*	_	_	432	_	-
wsj_1934.en	0	11	National	NNP	*	_	_	432	_	-
wsj_1934.en	0	12	Institute	NNP	*	_	_	429	_	-
wsj_1934.en	0	13	of	IN	*	_	_	432	_	-
wsj_1934.en	0	14	Health	NNP	*	_	_	433	_	-
wsj_1934.en	0	15	and	CC	*	_	_	428	_	-
wsj_1934.en	0	16	by	IN	*	_	_	435	_	-
wsj_1934.en	0	17	university	NN	*	_	_	438	_	(2)
wsj_1934.en	0	18	funds	NNS	*	_	_	436	_	-
wsj_1934.en	0	19	,	,	*	_	_	440	_	-
wsj_1934.en	0	20	and	CC	*	_	_	422	_	-
wsj_1934.en	0	21	that	IN	*	_	_	440	_	-
wsj_1934.en	0	22	Fujisawa	NNP	*	_	_	445	_	(16)
wsj_1934.en	0	23	did	VBD	*	_	_	445	_	-
wsj_1934.en	0	24	n't	RB	*	_	_	445	_	-
wsj_1934.en	0	25	give	VB	*	_	_	441	_	-
wsj_1934.en	0	26	the	DT	*	_	_	447	_	(11
wsj_1934.en	0	27	hospital	NN	*	_	_	445	_	11)
wsj_1934.en	0	28	any	DT	*	_	_	449	_	-
wsj_1934.en	0	29	grants	NNS	*	_	_	445	_	-
wsj_1934.en	0	30	.	.	*	_	_	422	_	-

wsj_1934.en	0	0	He	PRP	*	_	_	452	_	(8)
wsj_1934.en	0	1	said	VBD	*	_	_	0	_	-
wsj_1934.en	0	2	that	IN	*	_	_	452	_	-
wsj_1934.en	0	3	the	DT	*	_	_	456	_	(13
wsj_1934.en	0	4	research	NN	*	_	_	456	_	(17)
wsj_1934.en	0	5	team	NN	*	_	_	457	_	13)
wsj_1934.en	0	6	had	VBD	*	_	_	453	_	-
wsj_1934.en	0	7	no	DT	*	_	_	460	_	-
wsj_1934.en	0	8	financial	JJ	*	_	_	460	_	-
wsj_1934.en	0	9	stake	NN	*	_	_	457	_	-
wsj_1934.en	0	10	in	IN	*	_	_	460	_	-
wsj_1934.en	0	11	the	DT	*	_	_	463	_	(3
wsj_1934.en	0	12	drug	NN	*	_	_	461	_	3)
wsj_1934.en	0	13	.	.	*	_	_	452	_	-

wsj_1934.en	0	0	``	``	*	_	_	497	_	-
wsj_1934.en	0	1	We	PRP	*	_	_	468	_	(13)
wsj_1934.en	0	2	've	VBP	*	_	_	468	_	-
wsj_1934.en	0	3	known	VBN	*	_	_	478	_	-
wsj_1934.en	0	4	for	IN	*	_	_	468	_	-
wsj_1934.en	0	5	six	CD	*	_	_	471	_	-
wsj_1934.en	0	6	months	NNS	*	_	_	469	_	-
wsj_1934.en	0	7	the	DT	*	_	_	473	_	-
wsj_1934.en	0	8	effect	NN	*	_	_	468	_	-
wsj_1934.en	0	9	of	IN	*	_	_	473	_	-
wsj_1934.en	0	10	this	DT	*	_	_	476	_	(3
wsj_1934.en	0	11	drug	NN	*	_	_	474	_	3)
wsj_1934.en	0	12	,	,	*	_	_	478	_	-
wsj_1934.en	0	13	and	CC	*	_	_	497	_	-
wsj_1934.en	0	14	our	PRP$	*	_	_	480	_	(13)
wsj_1934.en	0	15	advice	NN	*	_	_	485	_	-
wsj_1934.en	0	16	to	TO	*	_	_	480	_	(18
wsj_1934.en	0	17	our	PRP$	*	_	_	483	_	(13)
wsj_1934.en	0	18	people	NNS	*	_	_	481	_	18)
wsj_1934.en	0	19	has	VBZ	*	_	_	485	_	-
wsj_1934.en	0	20	been	VBN	*	_	_	478	_	-
wsj_1934.en	0	21	not	RB	*	_	_	487	_	-
wsj_1934.en	0	22	to	TO	*	_	_	485	_	-
wsj_1934.en	0	23	buy	VB	*	_	_	487	_	-
wsj_1934.en	0	24	the	DT	*	_	_	490	_	(16
wsj_1934.en	0	25	company	NN	*	_	_	492	_	-
wsj_1934.en	0	26	's	POS	*	_	_	490	_	16)
wsj_1934.en	0	27	stock	NN	*	_	_	488	_	-
wsj_1934.en	0	28	,	,	*	_	_	497	_	-
wsj_1934.en	0	29	''	''	*	_	_	497	_	-
wsj_1934.en	0	30	Dr.	NNP	*	_	_	496	_	(8
wsj_1934.en	0	31	Starzl	NNP	*	_	_	497	_	8)
wsj_1934.en	0	32	said	VBD	*	_	_	0	_	-
wsj_1934.en	0	33	,	,	*	_	_	497	_	-
wsj_1934.en	0	34	adding	VBG	*	_	_	497	_	-
wsj_1934.en	0	35	that	IN	*	_	_	499	_	-
wsj_1934.en	0	36	profiting	VBG	*	_	_	504	_	-
wsj_1934.en	0	37	from	IN	*	_	_	501	_	-
wsj_1934.en	0	38	FK-506	NNP	*	_	_	502	_	(3)
wsj_1934.en	0	39	would	MD	*	_	_	500	_	-
wsj_1934.en	0	40	n't	RB	*	_	_	504	_	-
wsj_1934.en	0	41	be	VB	*	_	_	504	_	-
wsj_1934.en	0	42	ethical	JJ	*	_	_	506	_	-
wsj_1934.en	0	43	.	.	*	_	_	497	_	-

#end document 